Morningstar
•
Apr 29, 2026
Intellia Therapeutics, Inc.: Intellia: FDA Lifts Phase 3 Hold for ATTR-CM Trial; Positive Long-Term Data for Lonvo-Z
Summary
Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It’s evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, heredita
Upgrade to begin using premium research reports and get so much more.
Exclusive reports, detailed company profiles, and best-in-class trade insights to take your portfolio to the next level
UpgradeRelated Reports
Analyst Report: Illumina, Inc.
May 01, 2026
•
ILMN
SRPT: What does Argus have to say about SRPT?
Apr 29, 2026
•
SRPT
SDGR: What does Argus have to say about SDGR?
Apr 29, 2026
•
SDGR
Analyst Report: Vertex Pharmaceuticals Incorporated
Apr 27, 2026
•
VRTX
Analyst Report: CRISPR Therapeutics AG
Apr 24, 2026
•
CRSP
